ClinicalTrials.gg
RecruitingNCT07131059Updated Aug 10, 2026

MRD-positive AML Clinical Study

An interventional study of Ivosidenib and Gilteritinib in AML, Adult, sponsored by Institute of Hematology & Blood Diseases Hospital, China. Recruiting at 1 site in China. Open to participants aged 14 Years and older. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by Institute of Hematology & Blood Diseases Hospital, China · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
537
Allocation
Randomized
Ages
14 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 22 studies testing ivosidenib in Leukemia, Myeloid, Acute — 14 open to participants now, 19 under way, 4 of them phase 3. ivosidenib · Leukemia, Myeloid, Acute.

Planned enrollment
3rd of 22
537 · median 72
Started
2024
the only one that year
No phase
Only one
of the 22
Primary completion
2028-05
later than 14 of 18 live
Registered
16th of 22
by date
Lead sponsor
1 of 22
Institute of Hematology & Blood Diseases Hospital, China

Among the 22 studies testing ivosidenib in Leukemia, Myeloid, Acute, this one is the 3rd largest by planned enrollment, is the only one that started in 2024, is the only one with no phase, reaches primary completion later than 14 of the 18 other live ones, and was the 16th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

14 of the 22 studies testing ivosidenib in Leukemia, Myeloid, Acute are open now, in 8 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About ivosidenib

ivosidenib: first FDA approval 2018 (TIBSOVO), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 14 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing ivosidenib in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

This clinical trial is a platform-type clinical study intended to investigate the efficacy and safety of MRD-positive acute myeloid leukemia patients after comprehensive treatment, which includes but is not limited to the following drugs and protocols: Chemotherapy, small molecule targeted drugs, demethylation drugs, liposome drugs and the combination of these drugs to form a combination of treatment regimen, the specific treatment regimen will be updated according to the results of this trial and the latest research progress at home and abroad.

Read the detailed description

Patients aged 14 years or older with diagnosed AML (non-M3) who have achieved complete remission in bone marrow morphology but are positive for minimal residual disease by flow cytometry or have the following genetic mutations that can be detected by PCR: NPM1 mutation, IDH1/2 mutation, DEK-NUP214 (DEK-CAN), RUNX1-RUNX1T1(AML 1-ETO), or CBFβ-MYH 11[4]. NGS can detect mutations such as FLT3.

For eligible patients, the treatment plan is selected by the doctor in charge according to the specific conditions of the patient. During the treatment, patients can have hematopoietic stem cell transplantation at any time.

This study compared relapse-free survival and overall survival of MRD-positive patients after effective and persistent MRD treatment, and based on the results, observed the efficacy and safety of different treatment regiments for MRD-positive AML patients.

03

Conditions studied

  • AML, Adult

Keywords

  • Measurable Residual Disease
04

Who can participate

Ages eligible
14 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • AML (non-M3) compliant with WHO (2016) standards;
  • In morphological complete remission.
  • Mrd-positive patients: including bone marrow flow cytometry, PCR quantification of NPM1 mutations, PCR quantification of fusion genes (RUNX 1-RUNX1T1, CBFB-MYH11 and DEK-NUP214), or NGS detection of FLT3 mutation positive.
  • Age over 14 years old, male or female. must be signed prior to the commencement of all specific study procedures, and for those 14 years of age and older, informed consent must be signed by the patient or an immediate family member. Considering the patient's condition, if the patient's signature is not conducive to the treatment of the condition, the informed consent shall be signed by the legal guardian or the patient's immediate family.

Exclusion criteria

Exclusion Criteria:

  • Patients who intend to undergo hematopoietic stem cell transplantation within 4 weeks
  • The diagnosis is APL
  • Those who were not considered suitable for inclusion by the researchers.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
537 participants (estimated)

Study arms

  • Experimental
    With lDH1 gene mutation

    Ivosidenib 500mg/d: d1-28 ;Azacitidine 75mg/m2/d: d1-7;Venetoclax 600mg/d: d1-14

    Drug: Ivosidenib · Drug: Venetoclax · Drug: Azacitidine

  • Experimental
    FLT3 gene mutation

    Gilteritinilb 120mg/d: d1-28; Venetocax 400mg/d: d1-7;Azacitidine 75mg/m2/d : d1-7

    Drug: Gilteritinib · Drug: Venetoclax · Drug: Azacitidine

  • Experimental
    NPM1 mutation or IDH2 mutation

    Azacitidine 75mg/m2/d: d1-7;Venetoclax400mg/d: d1-21 or Cytarabine 20mg/m2/d : d1-10;Venetoclax 600mg/d: d1-21

    Drug: Venetoclax · Drug: Cytarabine · Drug: Azacitidine

  • Experimental
    c-kit mutation

    Avapritinib 200mg/ day, 28 days a course; Azacitidine 75mg/m2/d: d1-7

    Drug: Avapritinib · Drug: Azacitidine

  • Experimental
    Daunorubicin/Mitoxantrone/Idarubicin+Cytarabine +Venetoclax

    Cytarabine 100mg/m2/d, d1-5; Daunorubicin 45mg/m2/d,d1-2; or Idarubicin 10mg/ m2/d,d1-2; or Mitoxantrone 8mg/ m2/d d1-2; Venetoclax 400mg d1-7

    Drug: Venetoclax · Drug: Daunorubicin · Drug: Cytarabine · Drug: Idarubicin · Drug: Mitoxantrone

  • Experimental
    Cytarabine+Homoharringtonine+Venetoclax

    Cytarabine 100mg/ m2/d, d1-5; Homoharringtonine 2mg/ m2 d1-5; Venetoclax 400mg d1-7

    Drug: Venetoclax · Drug: Cytarabine · Drug: Homoharringtonine

  • Experimental
    Venetoclax+Azacitidine/Venetoclax+Cytarabine

    Azacitidine75 mg/m2 day1-7;Venetoclax 400mg day1-21 or,Cytarabine 20mg/m2 /day,day1-10; Venetoclax 600mg day1-21

    Drug: Venetoclax · Drug: Cytarabine · Drug: Azacitidine

  • Experimental
    JAK2 or CSF3R T618I mutation

    Azacitidine 75 mg/m² on days 1-7 Ruxolitinib 20 mg twice daily, 28-day cycle

    Drug: Azacitidine · Drug: Ruxolitinib

  • Experimental
    N-RAS and NF1 mutations

    Azacitidine 75 mg/m² on days 1-7 Tunlametinib 12 mg twice daily, 28-day cycle

    Drug: Azacitidine · Drug: Trametinib

Interventions

06

What researchers measure

Primary outcomes

  1. relapse-free survival rate

    Time frame: up to 6 months

Secondary outcomes

  1. Measurable Residual Disease

    Time frame: up to 6 months

  2. Proportion of MRD turning negative

    Time frame: up to 6 months

  3. Overall survival(OS ) rate

    Time frame: From the time the patients participated in the clinical trial until the patient died

  4. Cumulative relapse rate

    Time frame: From the time the patients participated in the clinical trial until the patient relapsed

  5. Adverse Events (AEs)

    Time frame: up to 2 years

  6. The incidence of adverse events such as serious infections during treatment

    Time frame: up to 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for May 2028, 47 months after the start.

Of 132 non-industry interventional studies with no phase under Leukemia, Myeloid, Acute, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 128. This study's planned 47 months is close to that.

Counting every sponsor, half of 139 studies reached it within 47 months; a quarter within 25 and three quarters within 123.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2024
First posted
Aug 20, 2025
StartActual
May 11, 2024
Primary completionEst.
May 10, 2028
CompletionEst.
Oct 30, 2028
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07131059
Responsible party
Sponsor
First posted
Aug 20, 2025
Start date
May 11, 2024
Primary completion
May 10, 2028 (estimated)
Completion
Oct 30, 2028 (estimated)
Last update
Aug 10, 2026

Study contacts

Hui Wei, Doctor
Contact
weihui@ihcams.ac.cn
13132507161
Huui Wei, doctor
principal investigator · Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ivosidenib · Gilteritinib · Venetoclax · Avapritinib · Daunorubicin · Cytarabine · Idarubicin · Mitoxantrone · Homoharringtonine · Azacitidine · Ruxolitinib · Trametinib

Start the discussion